Celularity (CELU) Total Liabilities (2018 - 2025)
Celularity (CELU) posted quarterly Total Liabilities of $145.4 million for Q4 2025, up 17.4% year-over-year from $123.8 million in Q4 2024, and up 8.23% quarter-over-quarter from $134.3 million in Q3 2025.
Celularity (CELU) Total Liabilities (2018 - 2025) Analysis & Trends
Celularity (CELU) has reported Total Liabilities for 8 consecutive years, with $145.4 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Total Liabilities rose 17.4% year-over-year to $145.4 million; the TTM figure through Dec 2025 stood at $145.4 million (up 17.4% YoY), while the FY2025 annual figure was $145.4 million, up 17.4% from the prior year.
- Total Liabilities climbed to $145.4 million in Q4 2025 per CELU's latest filing, from $134.3 million in the prior quarter.
- Across five years, Total Liabilities topped out at $352.1 million in Q3 2021 and bottomed at $39.8 million in Q1 2021.
- Historically, Total Liabilities has averaged $171.6 million across 5 years, with a median of $134.4 million in 2025.
- Annual changes were most pronounced in 2021 — Total Liabilities soared 925.25% — and 2023, when it tumbled 54.18%.
- Celularity's Total Liabilities stood at $314.7 million in 2021, then plunged by 35.76% to $202.2 million in 2022, then slumped by 49.09% to $102.9 million in 2023, then gained by 20.32% to $123.8 million in 2024, then gained by 17.4% to $145.4 million in 2025.
- Business Quant data shows CELU's Total Liabilities at $145.4 million in Q4 2025, $134.3 million in Q3 2025, and $145.8 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.35 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 10.03 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 3.22 Bn |
| 10 | Celularity | 20.90 Mn | 14.72 Mn | -3.27 Mn | 145.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 145.39 Mn |
| Sep 30, 2025 | 134.33 Mn |
| Jun 30, 2025 | 145.78 Mn |
| Mar 31, 2025 | 134.38 Mn |
| Dec 31, 2024 | 123.85 Mn |
| Sep 30, 2024 | 111.56 Mn |
| Jun 30, 2024 | 107.68 Mn |
| Mar 31, 2024 | 112.57 Mn |
| Dec 31, 2023 | 102.93 Mn |
| Sep 30, 2023 | 126.95 Mn |
| Jun 30, 2023 | 127.92 Mn |
| Mar 31, 2023 | 206.79 Mn |
| Dec 31, 2022 | 202.17 Mn |
| Sep 30, 2022 | 272.88 Mn |
| Jun 30, 2022 | 279.19 Mn |
| Mar 31, 2022 | 344.30 Mn |
| Dec 31, 2021 | 314.71 Mn |
| Sep 30, 2021 | 352.07 Mn |
| Jun 30, 2021 | 47.45 Mn |
| Mar 31, 2021 | 39.77 Mn |